readthroughSign in
Nov 12, 2026Clinical readout

Traws reports final Phase 2a ratutrelvir data, completes TXM tablet bridging study

Traws Pharma said ratutrelvir showed no viral rebound and fewer side effects than PAXLOVID in a 92-patient COVID-19 study, and will seek an FDA path for PAXLOVID-ineligible patients.

Traws Pharma announced on November 12, 2026 the final results of its 92-patient Phase 2a study of ratutrelvir, an investigational oral Mpro/3CL protease inhibitor for COVID-19, along with completion of a bridging study for a tablet formulation of tivoxavir marboxil (TXM), its once-monthly influenza prophylaxis candidate.

The trial randomly assigned 62 subjects eligible for PAXLOVID to take either ratutrelvir at 600 mg daily for 10 days or PAXLOVID (nirmatrelvir/ritonavir) for 5 days, and separately tested ratutrelvir in a cohort of 30 subjects who were ineligible for PAXLOVID, mostly due to drug interactions.1 Among PAXLOVID-eligible patients, median time to sustained symptom resolution was 13.5 days for ratutrelvir compared with 14.5 days for PAXLOVID.1 Viral RNA decline was similar between arms with no rebound through Day 28, and treatment-related adverse events occurred in 1 of 32 ratutrelvir patients versus 4 of 30 PAXLOVID patients.1

In the PAXLOVID-ineligible group, which skewed older with more cardiovascular and pulmonary conditions, viral clearance was similar to the randomized arms, median symptom resolution took 14.0 days, and no treatment-related adverse events were reported.1

Traws said it plans to pursue regulatory discussions. The company intends to discuss with the FDA a registration approach centered on adults at high risk for severe COVID-19 who cannot take PAXLOVID, including a possible adaptive Phase 2b/pivotal study design and Fast Track designation.1

On the influenza side, Traws completed a healthy-volunteer bridging study in Australia under an open IND for a compressed tablet form of TXM, finding exposure comparable to the powder-in-capsule version, good tolerability, and support for a once-monthly dosing schedule.1 Separately, the company repeated toxicology testing using the Pig-a gene mutation assay in two rat studies, finding no mutations at doses up to 500 mg/kg, a margin of about 125-fold over planned clinical exposure, and plans to resubmit the updated toxicology package to regulators in the fourth quarter of 2026.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.